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3INTRODUCTION
Carcinoma cervix is the most common cancer in the female population in the non-
metropolitan cities in India. Breast cancer ranks second and carcinoma cervix ranks
seventh according to incidence of cancers around the world.1 According to IARC
GLOBOCAN worldwide cancer incidence and mortality database,  the incidence of
carcinoma cervix in the world is estimated to around 5.2 million new  cases diagnosed
annually with a mortality of 2.6 million cases per year. The annual incidence of cervical
carcinoma is on the rise with the emergence of oncogenic HPV subtypes which is one of
the etiological factors for this cancer.
Persistent HPV infection of the metaplastic cells in the cervical transformation
zone leading to formation of an insitu lesion and progression to an invasive carcinoma
with a continued infection are the steps involved in the multistep carcinogenesis. With the
incidence of infection common in young women , the risk of invasive carcinoma also
peaks or plateaus within 35-55 years with a latency of 5-10 years.2
The advent of newer screening modalities has improved the chances of early
diagnosis and treatment of this deadly disease, thus enhancing the quality of their survival
in these patients. Although great progresses have been seen in the screening techniques,
surgical modalities and newer chemotherapy regimens for cancer cervix, the exact
molecular mechanism of carcinogenesis is not fully elucidated. Hence the need for an
4understanding of a potential molecular mechanism becomes essential in this modern era
of oncology.
Biomarkers provide an approach to understanding the molecular mechanisms in
oncology. Their applications in screening, diagnosis, prognostication, prediction of
recurrences, and monitoring of therapy of cancers is emerging. Advances in genomics,
proteomics, metabolomics, and bioinformatics have revolutionized the search for
numerous putative markers that may be informative with regard to carcinoma cervix.
 One among them is the discovery of a class of “small non-coding RNAs” termed
as microRNAs (miRNAs) which are thought to greatly influence the molecular
pathogenetic mechanisms of various cancers. These are a small group of non-coding
RNAs which are essential for gene expression and are thought to regulate cell
proliferation and metabolism, cellular differentiation, cell death, DNA methylation and
chromatin modification, hematopoiesis, neuronal development and tumorigenesis. With
increasing evidence of altered microRNA profiles attributed to various cancers, the
microRNA expression signatures have been closely associated with disease patterns and
clinical outcomes.3
Using microarray analysis, altered expression of microRNAs is being evaluated in
carcinoma cervix patients.  In this study we evaluate and analyze the possible role of a
subset of microRNAs which may be consistently associated with carcinoma cervix
possibly playing a major role in tumorigenesis and may aid in the diagnosis and
prediction of the clinical outcome.
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6AIMS & OBJECTIVES
The principal aims of our study are:
1. To assess the feasibility of extracting microRNA in carcinoma cervix tumor
samples.
2. To study the of miR-196a-5p expression profiles in various tumor samples
of carcinoma cervix.
3. To compare miR-196a-5p expression profiles in relation with the tumor
characteristics and clinical behavior of carcinoma cervix.
4. To analyse of miR-196a-5p expression profiles in relation to HPV status of
the tumor samples studied.
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8REVIEW OF LITERATURE
Carcinoma cervix represents the fifth most common tumor among all
cancers and the second most common tumor in the female genital tract accounting for an
annual incidence of more than 2 million new cases worldwide. Carcinoma of cervix was
the leading cause of mortality in females next to breast cancers two decades back. With
the invent of screening procedures such as PAP smears, colposcopic and visual
examination of the cervix using acetic acid or Lugol’s iodine, the frequency at which
carcinoma cervix is detected at a precancerous level has tremendously risen.
While there are an estimated 11,000 new cases of invasive carcinoma in the
United States annually, there are nearly 1 million precancerous lesions of varying grade
that are discovered yearly by cytologic examinations. Thus, it is evident that Pap smear
screening not only has increased the detection of potentially curable, low-stage cancers
but has also allowed the detection and eradication of preinvasive lesions, some of which
would have progressed to invasive cancer if not detected and treated.
Human papilloma virus (HPV) is the main etiological factor in the causation of
carcinoma cervix, with the low risk subtypes 6, 11, 42, 43 and 44 causing condyloma or
genital warts and the high risk subtypes 16 and 18 accounting for 80% of carcinoma
cervix and subtypes 31, 33, 35, 45, 52 and 58 accounting for another 20% of the cases.4
(Fig.1)
9The risk factors for carcinoma cervix are related to both host and viral characteristics
such as HPV exposure, viral oncogenicity, efficiency of immune response, and presence
of co-carcinogens.2 These include:
? Multiple sexual partners
? A male partner with multiple previous or current sexual partners
? Young age at first intercourse
? Persistent infection with a high oncogenic risk HPV 16 or HPV18.
? Immunosuppression
? Certain HLA subtypes
? Use of nicotine and oral contraceptives
Fig1: Epidemiological data showing the burden of HPV in carcinoma cervix
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           The vast majority of cancer of the cervix is squamous cell carcinoma accounting
for 70–80% of invasive carcinomas, adenocarcinoma and adenosquamous carcinoma
comprising 10–15% of all cases, and the rest another 10–15%.
The World Health Organization (WHO) recognizes three general categories of
invasive carcinoma of the cervix: squamous cell carcinoma, adenocarcinoma, and ‘‘other
epithelial tumors’’.5
The histological classification is as follows :
? “Squamous cell carcinoma
o Microinvasive (early invasive) squamous cell carcinoma
o Invasive squamous cell carcinoma
? Keratinizing
? Nonkeratinizing
? Basaloid
? Verrucous
? Warty
? Papillary
? Squamotransitional
? Lymphoepithelioma-like carcinoma”
? “Adenocarcinoma
o Usual type adenocarcinoma
o Mucinous adenocarcinoma
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? Endocervical type
? Intestinal type
? Signet-ring type”
o Minimal deviation
o Villoglandular
o Endometrioid adenocarcinoma
o Clear cell adenocarcinoma
o Serous adenocarcinoma
o Mesonephric adenocarcinoma
? Other epithelial tumors
o Adenosquamous carcinoma
? Glassy cell variant
o Adenoid cystic carcinoma
o Adenoid basal carcinoma
o Neuroendocrine tumors
? Carcinoid
? Atypical carcinoid
? Small cell carcinoma
? Large cell neuroendocrine carcinoma
o Undifferentiated carcinoma
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Other tumors which are included are mesenchymal tumors and tumor like
conditions, mixed epithelial and mesenchymal tumors, melanocytic tumors,
miscellaneous tumors which include tumors of germ cell type, lymphoid and
hematopoietic tumors and secondary tumors.
Molecular mechanism in HPV carcinogenesis:
Integration of the HPV genome with the host genome plays a pivotal role in the
oncogenesis of HPV 16 and 18 infection in the cervix. Cells with the viral genome
integration showed more genomic instability as this process interrupts the viral DNA
within the E1/E2 open reading frame, leading to loss of E2 viral repressor protein and
overexpression of oncoproteins E6 and E7.
The oncogenic potential is related to the products of two viral genes E6 and E7
interacting with various growth regulating proteins encoded by protooncogenes and
tumor-suppressor genes.  The E7 protein has a higher affinity for Rb gene, binding to it
and displacing the E2F transcription factors that are normally sequestered by Rb gene,
promoting progression through the cell cycle. Moreover, E7 also inactivates p21 which
allows activation cell cycle promoters such as cyclin D, cyclin dependent kinases
(CDK4) causing unchecked growth of cells.
Like E7, E6 also has an increased affinity for p53. The E6-p53 interaction happens
at the polymorphic site at aminoacid 72 in p53. This p53 Arg72 variant is more
susceptible to degradation by E6. Meanwhile E6 also promotes the degradation of a bax,
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a proapoptotic member of the bcl-2 family activating telomerase causing immortalization
of the tumor cells. To summarize, high risk HPV express oncogenic proteins which
eventually lead to a conglomerate of events inactivating tumor suppressors, activating
cyclins, inhibiting apoptosis and combating cellular senescence.6 (Fig.2)
Fig.2: Molecular mechanism of HPV oncogenesis
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Grading of carcinoma cervix:
Grade 1, well-differentiated squamous cell carcinoma - This tumor is composed of
cells that resemble “normal squamous epithelium, with frequent formation of
concentrically laminated keratin pearls and evident intercellular bridges and abundant
eosinophilic cytoplasm, and their nuclei show mild atypia, with inconspicuous nucleoli
and occasional mitosis”.
Grade 2, moderately differentiated squamous cell carcinoma - This tumor has cells
with “moderate amounts of cytoplasm and pleomorphic nuclei with Squamous
differentiation of the tumor cells still recognizable by occasional keratin pearl formation
and individual cell keratinization”. Mitoses are easily identified.
Grade 3, poorly differentiated squamous cell carcinoma - The tumor cells have a
“high nucleocytoplasmic ratio, marked nuclear pleomorphism, and abundant mitosis,
including some atypical forms but no keratin pearl formation identified”.
Staging of carcinoma cervix
The most widely accepted staging system for tumors of the cervix is the four-stage
system of the International Federation of Gynecologists and Obstetricians (FIGO)7. The
classification is as follows:
15
  FIGO Staging for carcinoma cervix
Stage Definition
16
17
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Management of carcinoma cervix
Locoregional treatment in cervical cancers are influenced by number of factors like
tumor size, histological features, evidence of lymph node metastasis, risk factors for
complications of surgery or radiotherapy and patient’s preference.
As a rule, high grade squamous intraepithelial lesions (HSILs) are managed with a
loop electroexcision procedure. Microinvasive cancers invading less than 3 mm (stage
IA1) are managed with conservative surgery like excisional conization or extrafascial
hysterectomy. Early invasive cancers (stage IA2,  IB1 and stage IIA) tumors are managed
with radical or modified radical hysterectomy, radical trachelectomy (if fertility is desired)
or radiotherapy.
Locally advanced cervical cancers (stages IB2, stages IIB -IVA) are managed by
combined chemoradiation therapy. Selected patients with centrally recurrent disease after
maximum radiotherapy may be treated with pelvic exenteration. Isolated pelvic
recurrences after hysterectomy are treated by irradiation. Metastatic carcinoma cervix
(stage IVB) are treated by chemotherapy.
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THE RNA FAMILY
The nucleus is the most important part of the cell which is largely made by
chromosomes. DNA is the component of the chromosomes that carry the "genetic
message," the blueprint for all the heritable characteristics of the cell and its descendants.
Each chromosome contains a segment of the DNA double helix.
The genetic message is encoded by the sequence of purine and pyrimidine bases in
the nucleotide chains. The text of the message is the order in which the amino acids are
lined up in the proteins manufactured by the cell. The message is transferred to
ribosomes, the sites of protein synthesis in the cytoplasm, by RNA. RNA differs from
DNA in that it is single-stranded and has uracil in place of thymine. (Fig.5)
Different mRNAs can be formed from a single gene, with each mRNA dictating
formation of a different protein. The proteins formed from the DNA blueprint include all
the enzymes, and these in turn control the metabolism of the cell. In short, DNA makes
RNA which makes proteins, and proteins are the cellular workhorses that carry out all the
crucial tasks. However, recently a group of RNAs called non coding small RNAs that
control the transcription and translation of protein-coding RNAs are found. MicroRNA is
one such member of the family of small RNAs which has been implicated in various
disease conditions. Various researches are been recently done to unravel the mystery of
these microRNAs, which may provide a further clue to the mysterious 98% of the human
genome that doesn’t direct the production of protein.
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Various other RNAs of the RNA family are transfer-messenger RNA, SmY RNA,
small Cajal body-specific RNA, Guide RNA, Y RNA, Telomerase RNA, Spliced leader
RNA, Ribonuclease P, Ribonuclease MRP which help in post transcriptional
modification or DNA replication and a few regulatory RNAs such as Piwi-interacting
RNA (piRNA), cis-natural antisense transcript, repeat associated RNA, 7SK RNA, trans-
acting siRNA are present in most eukaryotes, bacteria and animals.
Micro RNA:
MicroRNAs (miRNAs) are a class of non-coding RNA gene whose final product
is a ~22 nucleotide length functional RNA molecule. They play important roles in the
RNA
Non-coding
RNAs
Transcriptional
RNAs
tRNArRNA
Small RNAs
snRNAsnoRNAsiRNAmiRNA
Coding RNA
mRNA
Fig.5: Different members of the RNA family
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regulation of target genes by binding to complementary regions of messenger transcripts
to repress their translation or regulate degradation.18,19,20  miRNAs have been implicated
in cellular roles as diverse as developmental timing in worms, cell death and fat
metabolism in flies, haematopoiesis in mammals, and leaf development and floral
patterning in plants.21,22 They were first discovered in a nematode worm, Caenorhabditis
elegans and were shown to regulate expression of partially complementary mRNAs.23
Recent research have shown that  microRNAs are implicated in the pathogenesis
of various cancers in humans which had lead to the discovery of a whole array of
microRNAs and their relation to cellular function such as cellular differentiation,
proliferation and development, apoptosis, cell cycle regulation etc. These data imply that
the complexity of genomic control is greater than previously imagined, and that
microRNAs could represent a new order of genomic control.
Biogenesis of miRNA:
Biogenesis of miRs typically involves the transcription of pri-miRNA by RNA
polymerase II from the introns (referred to as mirtrons).Pri-miRNA forms a distinct
hairpin structure that is processed in the nucleus by Drosha to form a shorter Pre-miRNA
and then, exported to cytosol, whereby Dicer cleaves the hairpin to generate the mature
microRNA.
The mature microRNA loads onto the Argonaute protein in the RNA induced
silencing complex (RISC), which directs the mature microRNA toward its targets.
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Perhaps, the most important element in repression of gene expression by microRNAs is
the conserved Watson-Crick base pairing between nucleotide 2 to 7 at the 5’ end of the
microRNA, which is referred to as the Seed Sequence, and the target mRNA.
With the exception of the seed sequence, base pairing between microRNA and its
target mRNA need not be perfect which allows targeting of multiple different mRNAs by
a single microRNA. (Fig.6) Targeting of multiple different mRNAs leads to suppression
of expression of multiple proteins and hence, a number of secondary effects resulting
from the changes in the expression of the primary targets.24
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Fig 6: Biogenesis of microRNA with its functions
Functions of microRNA:
MicroRNAs are considered as key regulators of the transcriptional processes such
as cap40S initiation, joining of 60S ribosomal unit, elongation and premature termination
of ribosomal activity during transcription and two important post-transcriptional
mechanisms that sequence to downregulate gene expression.
24
? mRNA cleavage and degradation through destabilization mediated  by RNA
induced silencing complex (RISC) at the open reading frame of the target mRNA.
? Translational repression by a complementarity imperfect RISC binding at the 3’
untranslated regions of the target mRNA genes.
MicroRNAs are thought to play diverse roles in the regulation of many biological
processes such as development, proliferation, differentiation and apoptosis. The known
function of expressed miRNAs in an organism can be divided into three groups.25
? “The dysfunctional expression of specific microRNAs, known as oncomiRs which
has a major role in the  biogenesis of human malignancies”
? “The expression of particular microRNAs which has no functional consequence
unless some specific type of stress occurs”
? “The expressions of certain microRNAs are required to preserve metabolic
pathways, such as cholesterol and insulin biosynthesis”
With clinical parameters correlating with microRNA expression profiles, a wide list
of varied diseases like cardiovascular diseases, diabetes and cancers etc., have shown a
consistent association. Thus microRNAs serve as clinically relevant biomarkers and
accurate determination of their level of expression might describe the biological,
pathological and clinical roles of microRNA in health and disease.
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MICRORNAs & CANCER:
microRNAs and their relation to carcinogenesis has started with the discovery of
the first oncogenic microRNA described in 2005. (Fig.7) microRNAs which are related to
oncogenesis are hence referred to as “Oncomirs”. Recently, microRNA profiling and data
have elucidated the role of various microRNAs in different carcinogenic processes such
as cell proliferation, cytotoxicity, mutagenecity, metastatic potential etc., which has made
them a potential tool for diagnosis and prognostication of various cancers.
26
ONCOMIRS:
With the discovery of the gene silencing by microRNAs by Andrew fire and Craig
Mello for which they received the Nobel prize, the role of microRNAs in various disease
processes have been continuously explored. By current estimates, there are more than
3000 microRNAs which encode approximately about 1000 genes in humans accounting
only about 5% of the genome. Since microRNAs control various cellular processes of
growth differentiation and cell survival, it is not surprising that they play a role in
carcinogenesis.26
Fig 7: Historical evolution of microRNAs
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After the identification of two clustered miRNAs as the targets in human B-cell
chronic lymphocytic leukemias (B-CLL; the search for a microRNA fingerprint
investigation in normal and cancer cells by miRNA microarrays was developed. Since
then cancer-specific microRNA finger prints have been identified in every type of
analyzed cancer, including B-CLL, breast carcinoma, glioblastoma, hepatocellular
carcinoma, papillary carcinoma of thyroid, bronchogenic carcinoma, gastric carcinoma,
colonic carcinoma and endocrine pancreatic tumors, it represents that microRNAs are
involved in the initiation of the malignant process.27
miRNAs can participate in oncogenesis either by upregulating the expression of
oncogenes or by downregulating the expression of tumor suppressor genes. If a miRNA
inhibits the translation of an oncogene, a reduction in the quantity or function of that
miRNA will lead to overproduction of the oncogene product; thus, the miRNA acts as a
tumor suppressor. Conversely, if the target of a miRNA is a tumor suppressor gene, then
overactivity of the miRNA can reduce the tumor suppressor protein; thus, the miRNA
acts as an oncogene. The role of these oncomirs either as an oncogene or as a tumor
suppressor gene is predicted due to a mutational deregulation of the normal microRNA
activity leading onto their aberrant expression. (Fig.8)
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Many miRNAs reside in genomic regions involved in cancer, including minimal
regions of  loss of heterozygosity (LOH), minimal amplicons, or breakpoint cluster
regions.28 The aberrant expression in cancers is attributed to their location in these
genomic regions i.e, overexpressed oncogenic miRNAs are located in amplified regions
and the downregulated suppressor miRNAs are present in deleted regions. (Fig.9)
Fig.8: Molecular mechanisms in microRNA pathways
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These aberrantly expressed microRNAs, either overexpressed oncogenic miRs or
underexpressed tumor suppressor miRs along with various other protein coding genes
(PCGs) will dysregulate the cascade of cell cycle leading to inability of a cell to repair
cytogenetic abnormalities which will accumulate independently in different cells
generating clones of tumor cells with varying properties of tumor progression and
heterogenecity such as tumor growth, differentiation, invasion, metastasis and resistance
to chemotherapy. (Fig.10)
Fig 10: Oncogenesis by aberrantly expressed microRNAs
Fig.9: Mechanisms of microRNA induced carcinogenesis
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MicroRNAs expression levels assessed through oligonucleotide microarray analysis,
validated by RT-PCR has shown their association with various cell cycle controls and
checkpoints. A list of microRNAs and the genes they regulate has been shown below.29 (Fig.11)
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MICRORNAs IN CARCINOMA CERVIX:
Various microRNAs have been related in the sequential molecular mechanisms of
either HPV infection or tumor progression. A list of the varied microRNAs related either
to HPV or the various molecular mechanisms in oncogenesis of carcinoma cervix is
shown below.30 (Fig.12)
These microRNAs function either as oncomirs or as tumor suppressor microRNAs
by altering various downstream intracellular signaling pathways mediating critical
tumoral mechanisms such as growth and differentiation of cells, susceptibility to
apoptosis, lymphatic or vascular invasion and metastasis, susceptibility to
chemotherapeutic agents like cisplatin etc. and radiotherapy.
Fig.12: Frequently expressed microRNAs in cervical cancer
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Understanding the mechanism of microRNA and its role in carcinoma cervix thus
play a very important step in prediction and prognostication of the disease such as use of
serum microRNA as markers or aberrant hypermethylation of miRs in tissues. The huge
array of microRNAs have unraveled a possibility of therapeutics at a gene level, either by
inhibition of miRNAs by antisense miRNA oligonucleotides called antogomirs or
supplementing complementary miRNA nucleic acid sequences.31 The commonly
overexpressed and underexpressed miRs  in carcinoma cervix and their location in
chromosomes is listed below32,33,34 in Table 1.
Table 1. Expression of various microRNAs in carcinoma cervix
Overexpressed
miRNAs
Chromosome Underexpressed
miRNAs
Chromosome
miR-15a 13 miR-1 1
miR-15b 3 miR-7 10
miR-16 13 miR-10b 2
miR-17-5p 13 miR-29a 7
miR-19a 4 miR-30b 8
miR-20a 13 miR-100 11
miR-20b X miR-124 6
miR-21 17 miR-126 9
miR-27b 9 miR-138 13
33
miR-93 7 miR-143 5
miR-106a X miR-145 5
miR-133b 18 miR-149 2
miR-146 5 miR-194 4
miR-183 8 miR-195 19
miR-185 22 miR-214 1
miR-193b 16 miR-218 1
miR-196a 17 miR-376a 14
miR-199a 19 miR-422a 15
miR-203 14 miR-424 X
miR-210 11 miR-450 X
miR-224 X miR-451 17
miR-324-5p 17 miR-455 9
miR-372 11 miR-487b 14
miR-373 3 miR-495 14
miR-375 2 miR-574 4
miR-432 14
miR-641 19
miR-1286 22
miR-2392 26
34
Lui et al. in 2007 found out an increased expression of mir-21 and reduced
expression of mir-143 were reproducibly displayed in cancer samples among 6
substantially expressed miRNAs compared to normal cervix sample controls.
Interestingly, there were no viral-encoded microRNAs identified from the HPV infected
cells by molecular cloning approach. In addition, there were a few novel miRNAs and an
additional set of small RNAs, which do not meet the microRNA criteria were also
found.35
Wang X et al. in 2008 has found an aberrant expression of a few microRNAs such
as downregulation of growth suppressing mirs such as mir-143 and mir-145 and
upregulation of cell proliferating miR such as mir-146a plays an important role in
carcinoma cervix growth.36 Martinez et al. in 2008 found out that HPV 16 E6
downregulates mir-128 which is a major regulator of LAMB3 mRNA, leading to
consequent overexpression of the LAMB 3 protein contributing to tumorigenesis of
cancer cervix, suggesting that mir-128 regulates LAMB3 expression at the transcriptional
level.37
Lee et al. in 2008 analysed 70 different miRs with significantly different
expression in early stage invasive squamous cell carcinomas and found that an increased
mir-127 expression is significantly associated with lymph node metastasis. In addition,
they also reported that a novel class of chemically engineered oligonucleotides called
“antagomirs” such as anti-miR-199a that effectively silenced endogenous miRNAs in
35
vivo, leading to reduced carcinoma cervix cell growth and increased chemotherapeutic
response to cisplatin.38
Yang et al in 2009 has found that mir-214 level is downregulated in carcinoma
cervix which is validated by their reduced expression in human cancer cervix cell lines,
Hela. It was also found that mir-214 negatively regulates MEK3 and JNK1 mRNAs by
binding and targeting to their 3’UTR non-coding regions inhibiting Hela cell growth.39
               Wilting et al. in 2010 observed the tumor suppressive effects of mir-124 and
that methylation mediated silencing of mir-124 is associated with a high proliferation rate
in cervical cancer cell lines and hence was concluded that mir-124 may provide as a
valuable marker for risk stratification in the triage of high risk HPV positive women.40
Apoptosis is a major barrier that must be circumvented during malignant
transformation. Cancer cells evolve to evade apoptosis so that they can escape from being
cleared away by the surveillance system and can survive in crucial tumor
microenvironment. This mechanism is tightly regulated by a balance between pro-
apoptotic and anti-apoptotic proteins and microRNAs dysregulate this balance through
various methods leading to attenuation of tumoral response. Wang X et al. in 2009 found
out a compelling evidence for the first time that the HPV viral oncoprotein E6 is involved
in the regulation of cellular tumor suppressive miRNAs such as mir-34a. HPV E6
suppresses mir-34a by destabilizing and degrading the tumor suppressor p53 causing
induction of cancer cell growth and reduced apoptosis, providing new insights to the
molecular mechanisms of high risk HPV-induced carcinogenesis.41
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Liu L et al. in 2012 found a microRNA, mir143 that targets the anti-apoptotic
protein bcl-2, leading to tumor regression by promoting apoptosis.42 Overexpression of
bcl-2  is closely related to multiple epithelial tumors including cervical carcinomas
resulting from DNA damage and continued survival and subsequently aggregated
mutations and hence mir143 downregulation of bcl-2 causes tumoral regression.
            Cui et al. in 2012 found out that the overexpression of mir-125b promotes
downregulation of PIK3CD, inhibiting tumor growth and promoting apoptosis of
carcinoma cervix cells both in vitro and in vivo. PIK3CD (Phosphoinositide 3 kinase
catalytic subunit delta) is a special target in the mir-125b mediated apoptosis, regulating
the PI3K/Akt/mTor pathway.43
Wang F et al. in 2013 found out mir-214 causes increased tumor cell sensitivity
and cytotoxicity to cisplatin by downregulating the antiapoptotic protein bcl-2, inducing
apoptosis in cervical cancer cell line Hela and another cervical cancer cell line C-33A.
Furthermore, it was found that mir-214 enhanced the expression of proapototic proteins
Bax and caspases 9,3 and 8 inducing the intrinsic pathway of apoptosis by altering the
bax/bcl2 ratio.44
            Liu S et al. in 2013 found out an oncogene XIAP (X-linked inhibitor of apoptosis
protein) as a candidate target gene of the miR-7, which plays an important role in
regulating cellular proliferation and apoptosis. Hence overexpression of mir-7 in
carcinoma cervix lead to downregulation of XIAP leading on to suppressed cell viability
and promoted apoptosis in cervical cancer cell lines, Hela and C-33A.45  Huang et al. in
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2013 explored the upregulation of mir-101 causing inhibition of cell proliferation,
migration and invasion by increasing apoptosis of cervical cancer cells functionally
targeting cycloxygenase-2 (COX-2) protein.46
mir 218 is commonly downregulated in carcinoma cervix and hence
overexpression of mir-218 has been associated with reduced proliferation in carcinoma
cervix. Li et al. in 2012 found out mir-218 directly targets Rictor (Rapamycin-insensitive
companion of mTor), thus blocking the Akt-mTor signaling pathway, increasing the
chemosensitivity to cisplatin and decreased tumor cell growth and survival.47 Wei et al. in
2012 identified mir-17-5p as a tumor suppressor microRNA that downregulates a key
regulator of p53 posttranscriptional activity, TP53INP1(Tumor protein p53 induced
nuclear protein 1) by posttranscriptional repression. It was also found that there was an
inverse correlation between the levels of mir-17-5p and TP53INP1 in carcinoma cervix
tissues.48
              Tankyrase 2 (TNKS2), a new member of the telomere-associated poly (ADP-
ribose) polymerase (PARP) family, binds the telomere binding protein TRF1 and protects
the end of linear chromosomes. TNKS2 upregulation in tumor cells can increase telomere
length when overexpressed, which suggests that TNKS2 can promote tumor progress and
function as an oncogene. Kang et al. in 2012 found out a positive upregulation of TNKS2
by mir-20a which induces cell migration and invasion of cervical cancer cells.49
             Ma et al. in 2014 identified a serum microRNA, mir-205 which is consistently
elevated in carcinoma cervix patients and was correlated with poor tumor differentiation,
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metastasis and increased tumor stage.50 The concentration of serum mir-205 could
distinguish carcinoma cervix patients from normal individuals, making it a potential and
novel non-invasive biomarker for carcinoma cervix screening and disease progression.
            Wang WT et al. in 2014 demonstrated the differential expression of three specific
serum microRNAs such as miR-646, miR-141 and miR-542-3p before and after surgery
for cervical carcinoma. The levels of these serum markers were deregulated in carcinoma
cervix patients suggesting the possibility of serum microRNAs as effective markers in the
post-therapeutic monitoring of disease progression.51
Role of microRNA-196a in cervical cancer:
microRNA 196a is a class of microRNAs which was first cloned from osteoblast
sarcoma cells.52 The microRNA 196 family has 3 genes, miR196a-1, miR196a-2 and
miR196b, located at three paralogous loci in the mammalian HOX clusters which
encodes homeodomain-containing transcription factors regulating different genetic
programs during embryonic development.53 The class I homeodomain containing HOX
transcription factors encoded by those genes are expressed throughout embryogenesis in
a highly arranged temporal and spatial manner
which is responsible for embryonic patterning and involved in the control of cell identity,
cell growth and differentiation, as well as cell–cell and cell–matrix interactions.54
Upregulation of miR196a has been implicated in the pathogenesis of various
tumors by suppressing the expression of specific homeobox genes activating oncogenic
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pathways inside cells leading to tumor cell proliferation and migration, thereby inducing
tumor cell dissemination.55
Ruiz et al in 2014 determined the extreme complexity of family of microRNA
196a expression and downstream target genes in cervical carcinoma cells developing a
Gene Ontology Chart, (Fig.13)  describing the heterogeneity of microRNAs in cervical
carcinogenesis.56
Fig 13: Gene Ontology Chart depicting the complexity of upstream
regulators and downstream target genes related to miR196a
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Zhang J et al. in 2013 found out an inverse relationship between a target gene
netrin-4 (NTN4) and the levels of miR196a suggesting an overexpression of miR-196a
plays an important role in the regulation of cell proliferation and migration of cervical
cancer cells by targeting netrin-4.57
Hou et al. in 2014 found an upregulation in the expression of miR-196a directly
targets FOXO1 and p27Kip1 that are two key effectors of PI3K/Akt signaling pathways,
thus promoting cervical cancer proliferation. Upregulation of miR-196a was correlated
with advanced tumour stage and poor overall and recurrence-free survival in patients with
carcinoma cervix.58
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MATERIALS AND METHODS
This study was an analysis about the role of miRNAs expression profiles of
carcinoma cervix conducted on 58  patients and correlating the resultant data with various
parameters such as HPV status, grade, stage of the tumor and its relationship with
prognosis.
 Patients diagnosed with carcinoma cervix fitting the inclusion and exclusion
criteria were enrolled in the study after written informed consent.
Inclusion criteria
1. Patients with age of 18-75 years
2. All stages of carcinoma cervix
3. Cervical cancers of squamous cell histology only
Exclusion criteria
1. Cervical cancers with histology other than squamous
cell carcinoma
2. Patients unfit for any treatment
3. Recurrent or residual diseases
4. Second primary cancers
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CLINICAL DATA
All patients underwent a complete clinical examination, biopsy and
histopathological evaluation and relevant radiological investigations including
ultrasound and CT scan of abdomen and pelvis required for diagnosis and staging.
Cystoscopy was done in all cases with suspicion of urinary bladder involvement.
Examination under anaesthesia was done all cases to confirm the clinical staging.
All patients were staged according to FIGO staging system . Patients received
treatment according to their cancer site and stage as per standard practice. Microinvasive
carcinomas (Stage 1A ) were treated by type I hysterectomy and FIGO stages I B1 and II
A1 were treated by radical hysterectomy with bilateral pelvic lymphadenectomy .
Patients with FIGO Stage I B2,
II A2 , II B , III & IV A were treated by radical chemoradiation therapy. FIGO Stage IV
B was treated by systemic chemotherapy. 4 patients with FIGO stage I B2 and 6 patients
with FIGO II B were treated by 3 cycles of protocol preoperative chemotherapy followed
by surgery.
PATIENT FOLLOW-UP
All patients were followed monthly in the first year, every 2 months in the second
year, every 3 months in the 3rd year and twice yearly for the next 2 years and annually
thereafter. During each follow- up, patients undergo complete clinical examination after
relevant history to look for disease recurrence. Chest x-ray and ultrasound abdomen and
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pelvis is done in all patients annually. Imaging like CT scan of abdomen and pelvis and
cytology were not routinely recommended and was done in symptomatic patients as
required .
TUMOUR TISSUE SAMPLE
Tumour tissue samples were collected as described below at the time of diagnosis
from tumour biopsies and/or from the surgical specimens in patients who undergo
surgery. (Figure 1) Biopsy or surgical tissue sample (tumour tissue and tumour free
normal tissue from margins) was collected in a storage tube with 3 ml of RNAlater®
(Invitrogen Life Technologies, USA) solution and transferred to the Department of
Genetics, University of Madras, Chennai in icepacks. The amount of tumour tissue
needed for DNA/RNA studies is about 500-1000 mg.
The tissue is minced to smaller pieces and stored in the same RNAlater®
(Invitrogen Life Technologies, USA) solution at 4°C overnight for percolation. RNAlater
prevents RNA from getting degraded during transportation and storage. After 24hrs, the
RNAlater® (Invitrogen Life Technologies, USA) solution is decanted and the tissue is
stored at minus 20°C until isolation of RNA is done.
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RNA ISOLATION PROTOCOL
The frozen tissues are allowed to thaw on ice and excess of RNAlater®
(Invitrogen Life Technologies, USA) solution (or crystals if any) removed using a clean
tissue paper and transferred to sterile 2 ml Eppendorf tubes. One ml of TRIzol®
(Invitrogen Life Technologies, USA) and zirconium beads are added to the tissue sample.
The tubes are then subjected to repeated homogenization in MicroSmash® MS100
(Tomy Digital Biology Co.Ltd, Japan) homogenizer at 3500 rpm for 30 seconds with
equal intervals of 1 minute incubation on ice until a clear homogenate is obtained. The
homogenate is then transferred to a new sterile 2 ml Eppendorf tube and 0.2 ml of
chloroform is added. The mixture is vigorously shaken for 15-30 seconds until it turns
milky. All the steps of handling the tubes after step 4 should be carried out on ice.
The above mixture is centrifuged at 10,000 rpm for 20 minutes at 4°C. After
centrifugation, three layers are formed: a clear aqueous layer, a turbid organic layer and
an intermediate insoluble layer. The RNA containing upper aqueous layer is transferred
to a new 1.5 ml Eppendorf tubes and 0.5 ml of cold ethanol is added and shaken gently to
precipitate the RNA.
The tubes are then centrifuged again at 10,000 rpm for 20 minutes at 4°C to obtain
a white pellet of RNA. The supernatant is discarded. To these RNA pellets, 70% ethanol
is added, mixed gently and centrifuged again at 10,000 rpm for 20 minutes at 4°C.
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The isolated RNA is dissolved in DEPC treated Nuclease free distilled water and
stored at -20°C. RNA samples were quantified by Nanodrop 2000 UV-Vis
Spectrophotometer (Thermo Scientific, Germany). All the steps of handling the tubes
after homogenization are carried out on ice and RNase free environment. Utmost care is
taken to use RNAase free reagents and RNase free environment.
QUALITY VERIFICATION OF RNA
The quality verification of RNA is carried out to ensure RNA is free from DNA
and residual phenol/alcohol. The electrophoresis on a 0.7% agarose gel is used to verify
the quality of RNA.
Procedure for gel electrophoresis:
0.7 gram of agarsose is weighed and transferred into a 250 ml conical flask. 100
ml of 0.5x TAE buffer is added to it, stirred well and melted on a magnetic stirrer cum
hot plate until the agars’ dissolves completely. The appropriate sized gel tray and comb is
washed and wiped with 70% Ethanol. The gel tray is placed inside the casting unit. The
comb is placed on the gel tray and left on an even surface. After the agarose cools down
to hand bearing temperature, 5 µl of ethidium bromide is added and mixed well. It is
poured on the gel tray and allowed to polymerize. After polymerization the comb is
removed.
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The gel tray is then removed from the casting unit and placed in the
electrophoresis tank. 0.5x TAE buffer is poured into the tank until the gel gets immersed.
1 µl of each RNA sample is mixed with 2?l of 6x RNA loading dye (formaldehyde added
for denaturation of RNA) and 8ml of sterile double distilled water in a PCR tube. The
mixture is subjected to denaturation by warming at 65?C for 10 min. The RNA samples
are allowed to cool and loaded into the wells. The electrodes are connected; power set at
100 V and run for 20 minutes.
When bromophenol blue dye is in the middle of the gel, power is switched OFF. The
gel is taken to the transilluminator and observed under UV light and documented. The
good quality RNA is identified by two distinct bands (28s and 18s rRNA).
SPECTROPHOTOMETRY
The nucleic acid samples are analysed at 260nm and 280nm by using Nanodrop
Spectrophotometer (Thermo scientific, Germany). The concentration and purity of the
sample is analysed using the following formula:
CONCENTRATION OF RNA: Concentration of double stranded RNA sample (?g/µl)
= A260 x 40
PURITY OF RNA: Pure RNA = A260 /A280 ? 2.0. The observation of absorbance is
recorded at 280nm. The quality of the RNA was checked by the above mentioned
methods.
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MICRORNA EXPRESSION ANALYSIS
Complementary DNA (cDNA) was synthesized from the total RNA by using
SuperScript® III Reverse Transcriptase (Life Technologies, CA, USA) with 10ng RNA.
This cDNA was diluted 1:25 times for semi-quantitative PCR analysis and quantitative
PCR.
Primer Sequence
miR196a-5p
RTstemloop
primer
GTCGTATCCAGTGCGTCGAGTGACACGCAGAGCCACCTG
GGCAATTTGCACTGGATACGACCCCAAC
miR196a-5p
Forward primer
GCAGTAGGTAGTTTCATGTTGT
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                 Fig.14: Method of analysis using TaqMan Gene Expression Master Mix
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The relative expression was subsequently normalized to the median expression
values of control genes using the ?Ct calculation in ABI 7900HT Real time PCR using
TaqMan® Gene Expression Master Mix and miR196a-5p specific forward with Universal
reverse. (Fig.14) Data acquired from the PCR reactions was analyzed using RQ Manager
and the resulting text file was exported to DataAssist™ software (Applied Biosystems,
CA, USA).
TaqMan® Protocol:
The TaqMan® Protocol as described the supplier was used to analyze the
miRNAs. cDNA is first synthesized from the total RNA in 15 ?l reaction volumes. The
cDNA are then first incubated at 16°C for 5 minutes to anneal the stem loop primer and
then at 42 °C for 30 minutes. They are further incubated at 85 °C fir 10 minutes to
inactivate the enzymes. Each cDNA are then be amplified by qPCR in 20 ?l PCR
reactions containing 10 ?l of 2x TaqMan® Universal PCR Master Mix, 2 ?l of 10x
TaqMan® MicroRNA Assay mix and 1.5 ?l of reverse transcription product. The
reaction are carried out under the following conditions: 95 °C for 10 minutes and 40
cycles of 95 °C for 15 seconds and 60 °C for 1 minute using sequence specific primers.
Tumour tissue samples were collected from 119 patients with carcinoma cervix
from tissue biopsies and surgical specimens. Tissue sample from normal non cancerous
tissues were also collected from some patients and pooled to form a control sample.
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We were able to extract RNA from 72 tumour tissue samples. Gel Photos and
Ultraviolet Spectrometry were used to asses if the RNA was of sufficient quality and
quantity for miRNAs Expression Studies. Of these 72 tissue samples, 63 samples (52.9
%) had sufficient quantity and quality of RNA i.e., can be used for miRNAs Expression
studies.  58 patients with good quality RNA extracted from tumour biopsies were selected
for miR196a-5p expression study. Expression of miR196a-5p relevant to carcinoma
cervix based on available literature was analysed and compared with Clinical data of
these 58 patients. Controls used were RNU 44 and RNU 48 Expression and Pooled
Control Samples (normal tissues)
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STUDY DESIGN
Patients with carcinoma cervix
FIGO Staging
Tumor Biopsy
Squamous cell carcinoma
Differentiation (well differentiated, moderately differentiated ,poorly differentiated)
HPV status (HPV-16 &18)                                        microRNA 196a-5p
CORRELATION BETWEEN
1. Grade of the tumor and the HPV status
2. Grade of the tumor and the miRNA 196a-5p expression analysis
3. HPV status and the miRNA 196a-5p expression analysis
4. miRNA196a-5p expression analysis and prognosis
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STATISTICAL ANALYSIS
 The microRNA 196a-5p expression data from tumour tissues were expressed as
mean values and were compared with normal pooled control tissue samples and also
normalized with external control miRNAs. The HPV status with respect to each tumor
tissue was also studied and analyzed. Clinical data with the FIGO stage, histological
grade of tumour, type of treatment given and the response to treatment and survival on
followup were analyzed. Chi square test was employed for the comparison of group
characteristics and p < 0.05 was considered to be statistically significant. Statistical
analysis was done using SPSS 16® (IBM Inc, USA) and EXCEL 2007 ® (Microsoft,
USA).
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RESULTS
Purified microRNA extract from 58 patients with carcinoma cervix were analyzed.
These patients were categorized based on the stage of carcinoma cervix at the time of
presentation by FIGO staging and the histological grade of the tumor. Out of these 58
patients with squamous cell carcinoma of cervix, 9 patients (15.5%) presented at FIGO
Stage I, 21 patients (36.2%) at Stage II disease, 25 patients (43.1%) at Stage III and 3
patients (5.2%) with FIGO Stage IV at the time of presentation (Fig.15).
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Fig.15:  FIGO Stage of carcinoma cervix at the time of presentation
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Among these patients presenting with different stages of carcinoma cervix, 19
patients had a well differentiated squamous cell carcinoma (33%), 23 carcinoma cases
(40%) had a moderately differentiated tumor and 16 patients (27%) with a poorly
differentiated carcinoma (Fig. 16).
Among these 58 patients, 41 patients (71%) of them are positive for HPV 16, and
2 patients (3%) are positive for HPV 18. 3 patients (5%) of them were positive for both
and 12 patients (21%) were negative for both HPV 16 and HPV 18 (Fig.17).
33%
40%
27%
Fig 16: Grade of Squamous cell carcinoma
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To identify the dysregualtion of microRNA in cervical cancers, we attempted to
correlate the relationship between the 3 parameters - HPV status, the grade of the lesion
and the miR196-5p expression. The group of 58 patients who were categorized based on
the grade of the tumors is further correlated with the HPV status and miR expression
status.  The expression of miR in different HPV categories and the statistical significance
between these parameters is also studied.
HPV 16 +ve
71%
HPV 18 +ve
3%
HPV 16 & 18 +ve
5%
HPV 16 & 18 -ve
21%
Fig 17: HPV status in study samples
HPV 16 +ve HPV 18 +ve HPV 16 & 18 +ve HPV 16 & 18 -ve
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 Table 2: Grade of the tumor vs HPV Status
Grade of the tumor HPV status
HPV 16 + HPV 18 + HPV 16 & 18
+
HPV 16 & 18
-
Well differentiated 13 (31%) 0 0 6 (50%)
Moderately
differentiated
17 (42%) 0 2 (67%) 4 (33%)
Poorly differentiated 11 (27%) 2 (100%) 1 (33%) 2 (17%)
Total 41 2 3 12
From Table 2, it is evident that out of 41 patients with only HPV 16 positivity,
31% had a well differentiated tumor, 42% had a moderately differentiated tumor and 27%
had a poorly differentiated tumor. All the patients in the HPV 18 positivity group
presented with a poorly differentiated tumor. Among 3 patients who were positive for
HPV 16 & 18, 67% presented with a moderately differentiated carcinoma and 33% with a
poorly differentiated tumor. Out of 12 patients negative for both HPV 16 and 18, 50%
presented with a well differentiated tumor, 33% with a moderately differentiated tumor
and 17% with a poorly differentiated carcinoma. (Fig.18).
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Table 3: Grade of the tumor vs miR196a-5p expression
Grade of the tumor miR196a-5p expression
Upregulated Downregulated
Well differentiated 7 (18%) 12 (67%)
Moderately differentiated 18 (45%) 5 (28%)
Poorly differentiated 15 (37%) 1 (5%)
Total 40 18
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Fig 18: Grade of tumor vs HPV status
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The relative expression of miR196a-5p with respect to different grades of tumor is
analysed and tabulated in Table 3.  It is evident that out of 40 tumors which showed an
upregulation of miR, 18% of them were well differentiated tumors, 45% of them were
moderately differentiated and 37% were poorly differentiated. Among the tumors which
showed a downregulation of miR196a-5p, well differentiated tumors formed 67% with
moderately differentiated and poorly differentiated forming 28% and 5% respectively.
(Fig.19) There is a significant positive association observed between the grade of the
tumor and the expression of miR196a-5p with p value < 0.001 by Chi-square test.
The above data suggests that as the grade of the lesion progresses from a well
differentiated tumor towards a poorly differentiated carcinoma, a significant upregulation
of mir196a-5p is observed in the tumor samples.
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HPV status vs miR196a-5p expression:
The mean expression of miR196a-5p in relation to different HPV status is
analyzed in Table 4. The expression of miR196a-5p in patients was expressed as either
upregulated or downregulated. Out of 40 cases which showed an upregulation of
miR196a-5p, 75% of the cases were positive for HPV 16, 2.5% were positive for HPV
18, 7.5% were positive for both HPV 16 and 18 and 15% were negative for both HPV 16
and 18. Out of 18 cases which showed a downregulation of miR in the tumor samples,
61% of them were positive for HPV 16, 6% of them were positive for HPV 18 and 33%
of them were negative for both HPV 16 and 18. (Fig.20) However, in our studies there
was no statistically significant correlation found between the HPV status and the miR
expression of the individual tumors.
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Table 4: HPV status vs miR196a-5p expression
HPV status Expression of miR196a-5p in tumor
samples
Total No.
of HPV
casesUpregulated Downregulated
HPV 16 +ve 30 (75%) 11 (61%) 41
HPV 18 +ve 1 (2.5%) 1 (6%) 2
HPV 16 & 18 +ve 3 (7.5% 0 3
HPV 16 & 18 -ve 6(15%) 6 (33%) 12
Total miR expression in
HPV
40 18 58
miR196a-5p expression vs Prognosis on followup:
The mean expression of miR196a-5p and its relationship with the prognosis of the
disease on followup is analyzed in Table.5 and survival analysis was done by Kaplan
Meier method. The median follow up period was 18 months ( maximum – 53 months &
minimum- 3 months). It is evident that out of 40 cases showing an upregulated
expression of miR, 23 cases (57.5%) of the cases were alive & tumor free after treatment,
10 cases (25%) were alive with tumor recurrence, 2 cases (5%) were dead due to non
tumor causes and 5 cases (12.5%) were lost for followup. Out of the 18 cases that showed
a downregulation of expression of miR196a-5p, 15 cases (83.3%) were alive & tumor
64
free after treatment, 1 case (5.6%) had a tumor recurrence and 2 cases (11.1%) were lost
for followup. (Fig.21)
Table 5: miR expression vs prognosis on followup
miR 196a-5p
expression
Prognosis of patients on followup Total
patientsAlive -
Tumor free
Alive-Tumor
recurrence
Dead- Tumor
free
Lost for
followup
Upregulated 23 (57.5%) 10 (25%) 2 (5%) 5 (12.5%) 40
Downregulated 15 (83.3%) 1 (5.6%) 0 2 (11.1%) 18
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Kaplan-Meier survival analysis
Table 6: Case Processing Summary
Micro RNA 196a - 5p
Expression Total N N of Events
Censored
N Percent
Upregulated 40 10 30 75.0%
Downregulated 18 1 17 94.4%
Overall 58 11 47 81.0%
Table 7: Means for Survival Time
MicroRNA
Expression
Mean
Estimate Std. Error
95% Confidence Interval
Lower Bound Upper Bound
Upregulated 39.902 3.527 32.989 46.814
Downregulated 48.000 2.828 42.456 53.544
Overall 42.398 2.834 36.843 47.952
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Fig 22: Kaplan-Meier survival analysis
From the observed data, though there was an increase in the recurrence rate with cancers
showing an upregulated expression of miR196a-5p compared to that of those with a
downregulated expression, there was no statistically significant correlation observed
between the miR expression and the prognosis on followup as determined by Log Rank
test (p = 0.177).
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DISCUSSION
Carcinoma of cervix has been the most common tumor and is the one of the major
cause of mortality and morbidity in the female population. Human papilloma virus has
been implicated in the causation of carcinoma cervix and its relationship to the tumor has
been a field of extensive research in unraveling the possible mechanisms of oncogenesis.
Though various mechanisms have been postulated in HPV carcinogenesis, the exact
mechanisms which govern the molecular sequence remains still unclear and less
understood.
microRNAs are a group of endogenous non protein-coding RNAs that regulate
various intracellular signaling mechanisms such as stem cell differentiation, organ
development, cell death etc. are recently implicated with the causation of various cancers
59. Due to an aberrant expression, these microRNAs function either as oncogenes or as
tumor suppressor genes, suppressing or facilitating specific gene targets which could be
either a proto-oncogene or a tumor suppressor gene. Hence upregulation or
downregulation of various microRNAs are found to play a major role in the causation of
various cancers. miR196a-5p is a member of the mir196 family, a redundant sequence in
a genome, which is related to proliferation and migration of tumor cells by targeting
downstream regulatory pathways.
This study was a pilot study to assess the feasibility of doing microRNA 196a-5p
expression analysis in 58 patients with carcinoma cervix. Most studies on miRNAs
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expression in carcinoma cervix are of small sample size based on cancer cell line cultures
or few tissue samples. Also, the emphasis in these studies was to find out which miRNAs
where upregulated or downregulated.
By this analysis, we aimed at correlating the expression of this novel microRNA
196a-5p and its relationship to the possible parameters like grade of the tumor, HPV
status of the individual etc. that might help us in predicting the clinical behavior of the
patient, response to chemotherapy or radiotherapy and probability of a disease-free
survival period. This in future may help us prepare a commercially viable miRNAs
Expression analysis (either single or multiple) similar to gene based testing in cancers
(e.g. Oncotype DX and Mammaprint in breast cancer).
The methods of isolation of microRNA from tissue samples pose a great challenge
from the time of collection to the extraction of sufficient quantity of microRNA 196a-5p
from the particular tumor sample. Unlike DNA, RNA gets degraded rapidly when
removed from the body. Furthermore, enzymes which degrade RNA called RNAases are
found ubiquitously in the environment, that necessitates the immediate processing of
samples and freezing the samples in liquid nitrogen to at least -20º Celsius, using
solutions which degrade RNAses (e.g. RNAlater). The immediate processing and
maintenance of cold chain until the extraction of microRNA of such large number of
samples involves a larger cost and is time consuming.
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               To prevent RNA degradation, we used an RNAlater solution and
extracted purified RNA with good quality bands in Gel photos in 58 patients. During the
initial phase of the study, the extraction rate was only around 50 percent which improved
during the second half of the study with careful avoidance of sample mishandling and
early processing of samples.
                             Most studies use microarray technique to study their expression.
However microarray technique, though high throughput, is not a quantitative method and
has to be validated using other techniques like northern blot or PCR. We wanted to study
miRNAs expressions in a larger number of tumor samples. So we opted to study the
expressions of miRNA196a-5p based on our previous microarray data and available
literature by quantitative RT PCR based amplification of micro RNA expression.
                      In our analysis, out of 41 patients with only HPV 16 positivity, 31% had a
well differentiated tumor, 42% had a moderately differentiated tumor and 27% had a
poorly differentiated tumor. All the patients in the HPV 18 positivity group presented
with a poorly differentiated tumor. Among 3 patients who were positive for HPV 16 &
18, 67% presented with a moderately differentiated carcinoma and 33% with a poorly
differentiated tumor. Out of 12 patients negative for both HPV 16 and 18, 50% presented
with a well differentiated tumor, 33% with a moderately differentiated tumor and 17%
with a poorly differentiated carcinoma.
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                      Among 58 patients presenting with different stages of carcinoma cervix, 19
patients had a well differentiated squamous cell carcinoma (33%), 23 carcinoma cases
(40%) had a moderately differentiated tumor and 16 patients (27%) with a poorly
differentiated carcinoma. In our study, there was a significant positive correlation
observed (p<0.001) between the grade of the tumor and the mir196a-5p expression which
indicates that poorly differentiated carcinoma of cervix will show an upregulation in the
expression of miR196-5p as compared to that of well differentiated tumors.  Molecular
researches by Zhang et al. (2013. loc ?it) and Hou et al. (2014. loc ?it) also reveal the role
of upregulation of microRNA196a targets various downstream pathways which causes
progression of tumor cells, correlating with the findings of our study. Similarly, Lu J et
al. assayed microRNAs on poorly differentiated tumor samples with non-diagnostic
histologic appearance and found out that microRNA expression by microarrays could
establish an accurate diagnosis of poorly differentiated tumors which support the findings
in our study 60. This relationship of miR with the grade of the tumor explains the various
intracellular regulatory mechanisms on which microRNAs play an important role that
could cause the progression of the disease. Upregulation of mir196a-5p expression
associated with poorly differentiated carcinomas suggest that mir-196a-5p could be used
as a prognostic indicator.
                       The mean expression of miR196a-5p in relation to different HPV status
were analyzed. The expression of miR196a-5p in patients was expressed as either
upregulated or downregulated. Out of 40 cases which showed an upregulation of
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miR196a-5p, 75% of the cases were positive for HPV 16, 2.5% were positive for HPV
18, 7.5% were positive for both HPV 16 and 18 and 15% were negative for both HPV 16
and 18. Out of 18 cases which showed a downregulation of miR in the tumor samples,
61% of them were positive for HPV 16, 6% of them were positive for HPV 18 and 33%
of them were negative for both HPV 16 and 18. With respect to the miR expression in
HPV positive tumors, though most of the tumors that are positive for HPV 16, 18 or both
showed an upregulation of miR196a-5p as compared to that of tumors with negativity for
both HPV 16 & 18, there was no statistical significance observed between these two
parameters. This observation has been substantiated by a study done by Ruiz et al. (2014.
loc ?it) on cancer cell lines suggesting the presence of specific HPV does not influence
specific microRNA in cell lines, explaining the complexity and heterogeneity of
microRNAs.
The mean expression of miR196a-5p and its relationship with the prognosis of the
disease on followup was analyzed. It is evident that out of 40 cases showing an
upregulated expression of miR, 27 cases (67.5%) of the cases became disease free after
treatment, 6 cases (15%) had a recurrence of the disease, 2 cases (5%) were dead and 5
cases (12.5%) of the cases were lost for followup. Out of the 18 cases that showed a
downregulation of expression of miR196a-5p, 12 cases (67%) became disease free after
treatment, 1 case (6%) had a recurrence and 5 cases (27%) were lost for followup.
Though about two third of the tumors which showed either an upregulation or
downregulation of miR196a-5p expression were disease free on followup, there was no
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statistical significance observed between the miR expression against the prognosis of the
disease on followup. Since these patients were on a varied period on followup during the
study, this statistical insignificance could be analyzed over a longer followup period.
MicroRNA 196a expression has been correlated with various tumors such as
melanoma, oesophageal, laryngeal, pancreatic, lung and colorectal carcinomas. Most of
these tumors show an upregulated or an overexpression of this novel microRNA.
However in a few tumors there is a significant downregulation of miR196a which causes
progression of the tumor. These controversial expressions were explained by various
mechanisms, such as the heterogeneity of microRNA in these tumor cells with different
target genes which are involved in embryonic development and cellular remodeling such
as Homeobox genes (HOXC8, HOXA7, HOXD8, HOX A9 and HOXB8) and Actin and
Keratin. The extreme complexity of miR196a regulating the various downstream gene
targets as indicated previously in the Gene Ontology Chart (Fig.18) suggest that
carcinoma cervix and its relation with microRNA is a highly complex event and the
inability to ascertain a relationship between the HPV status and microRNA suggests that
presence of fine molecular events which are yet to be unraveled.
      Out of 58 patients representing a subset of female population in Chennai city
with the diagnosis of carcinoma cervix, HPV positivity was observed in 46 patients (
79%) and HPV negativity was observed in 12 patients (21%)  as against the prevalence
rate of 82.7% of HPV positivity  in invasive cervical cancers in Indian women as reported
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by Indian Human Papilloma virus & related cancers, Fact sheet – 2014 and more than
99% prevalence rate of HPV in western studies.
Hence further studies with a greater subset of population with carcinoma cervix
would give us an idea about the correlating factors between HPV status, level of
microRNA expression and the prognostic factors of the disease which would reveal the
intricate molecular mechanisms involved in carcinogenesis.
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    CONCLUSIONS
Based on this study the following conclusions are made.
(1) The extraction and analysis of microRNAs from carcinoma cervix patients is
feasible, provided proper care is ensured in transportation, storage and
processing of the samples.  Development of newer, simpler, more efficient,
safer and cost effective techniques are needed for storage, transportation,
extraction and analysis of microRNA.
(2) Altered expression of miR196a-5p has shown definite and significant positive
correlation with the grade of the tumor. Upregulation of mir196a-5p expression
associated with poorly differentiated carcinomas suggest that mir-196a-5p
could be used as a prognostic indicator.
(3)  There was no significant correlation observed between the grade of the tumor
and the HPV status of the individual.
(4) There was no significant correlation between the HPV status and miR-196a-5p
expression.
(5) There was no significant correlation observed between the prognosis of the
disease with respect to the expression of miR196a-5p.
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miR-196a-5p expression, if used in combination with other microRNAs with a
high diagnostic relevance can be used as a potential marker in the diagnosis, prediction
and prognostication of the disease.
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PATIENT PROFORMA
Name: Age: Sex: CD/COP No:
Performance status: Height: Weight: BSA:
Clinical features:
Imaging Report: HPE:
Stage (FIGO): IA1 / IA2 / IB1 / IB2 / IIA1 / IIA2 / IIB / IIIA / III B / IV
Tumor grade: Well / Moderately / Poorly / Undifferentiated / Unknown
Samples collected:
1. At diagnosis: Blood / Tumor tissue / Normal tissue Date:
2. Post Chemo/RT: Blood / Tumor tissue / Normal tissue Date:
3. At surgery: Blood / Tumor tissue / Normal tissue Date:
Treatment given:
1. Surgery 3. Chemoradiation
2. Radiotherapy 4. Chemotherapy
Follow up Record:
Date Follow-up
period
Status at followup
(Alive no disease/ Alive with disease/ Distant metastases/ Death/ LOFU)
Written Informed Consent
I ……………… hereby agree to participate in the study on microRNA expression
profiles in carcinoma cervix and agree to provide my Tumor/Blood samples. I have
been clearly explained about the procedure and have been explained well about the
study in my own language. I have also been told that I could withdraw from the study
at any time and I hereby declare that all my questions have been clarified.
Date:     Signature / Thumb impression

 Master chart
WD – well differentiated, MD – moderately differentiated , PD – poorly differentiated
S.No Name Age Sex Patient
ID
FIGO
stage
Grade Treatment given HPV
16
HPV
18
miR 196-5p
status
Status Followup
(Months)
1 VARATHAMMAL 58 F 156/11 IIB MD Chemoradiation - - Upregulated Alive -Tumor free 44
2 VADIVAMBAL 66 F 295/11 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 44
3 ADHILAKSHMI 75 F 383/10 IIIB WD Chemoradiation + - Upregulated Alive-Recurrence 53
4 JOTHI 48 F 348/11 IIB PD Chemoradiation - + Downregulated Alive -Tumor free 43
5 PARAMESHWARI 38 F 311/11 IIB WD Chemoradiation + - Downregulated Alive-Recurrence 44
6 MARAGHADAM 65 F 018/11 IIIB MD Chemoradiation - - Upregulated Alive -Tumor free 46
7 LAKSHMI 65 F 525/12 IIIB MD Chemoradiation - - Downregulated Lost follow up 11
8 VELLAKARCHI 65 F 117/12 IIB MD Chemoradiation + - Upregulated Alive-Recurrence 33
9 SHAKUNTHALA 48 F 1195/11 IIB MD Chemoradiation + - Upregulated Alive-Recurrence 40
10 LAKSHMI 50 F 1330/10 IIB MD Chemoradiation + - Upregulated Alive -Tumor free 48
11 CHINNAKULANTHAI 72 F 1773/12 IIIB MD Chemoradiation + - Upregulated Alive-Recurrence 30
12 PAPPA 57 F 681/10 IB1 WD Surgery + - Downregulated Alive -Tumor free 52
13 VASANTHA 48 F 854/12 IIB WD Chemoradiation - - Downregulated Alive -Tumor free 35
14 AMARAVATHY 75 F 1125/12 IB1 WD Surgery + - Downregulated Alive -Tumor free 30
15 BELA 45 F 1178/11 IB2 WD Chemotherapy + Surgery + - Upregulated Alive -Tumor free 40
16 SENTHAMARAI 56 F 1162/11 IIIB MD Chemoradiation + - Upregulated Alive -Tumor free 38
17 JAGDEESHWARI 30 F 1129/12 IIB MD Chemotherapy + Surgery + + Upregulated Dead – tumor free 16
18 RAJALAKSHMI 74 F 1178/12 IIIB MD Chemoradiation + - Upregulated Lost follow up 12
19 INBAVALLI 40 F 186/13 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 23
20 SARASWATHY 48 F 243/13 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 23
21 UNNAMALAI 45 F 159/13 IIIB PD Chemoradiation + - Upregulated Lost follow up 10
22 RAJAMMA 50 F 1162/12 IIB WD Chemo + Surgery + - Downregulated Alive -Tumor free 28
23 SELVI 45 F 580/13 IIIB WD Chemoradiation + - Upregulated Alive-Recurrence 18
24 CHINNA PONNU 50 F 630/13 IIB MD Chemotherapy + Surgery + - Downregulated Alive -Tumor free 22
25 DEVI 33 F 1349/12 IIB MD Chemotherapy + Surgery + - Upregulated Alive-Recurrence 29
26 ESHWARI 30 F 1127/12 IIB MD Chemotherapy + Surgery + + Upregulated Alive -Tumor free 23
27 RENUKA 37 F 1135/12 IIIB WD Chemoradiation + - Up regulated Alive -Tumor free 28
28 SUGHANTHINI 53 F 823/13 IIB WD Chemoradiation + - Up regulated Alive-Recurrence 20
 Master chart
WD – well differentiated, MD – moderately differentiated , PD – poorly differentiated
29 MARI 67 F 836/13 IV A PD Chemoradiation + - Upregulated Alive -Tumor free 20
30 PRABAVATHY 50 F 813/13 IIIB MD Chemoradiation + - Upregulated Alive -Tumor free 22
31 MARY 40 F 1352/13 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 17
32 KUPPU 40 F 1024/13 IIB MD Chemoradiation + - Downregulated Alive -Tumor free 18
33 AMARAVATHY 65 F 742/13 IIIB MD Chemoradiation + - Upregulated Alive -Tumor free 20
34 SARASU 45 F 155/13 IIB PD Chemoradiation + + Upregulated Alive-Recurrence 23
35 RANI 65 F 493/13 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 18
36 BAKKIYAM 60 F 1526/13 IB2 WD Chemoradiation + - Downregulated Alive -Tumor free 17
37 PAPAMMAL 60 F 149/14 IIIB MD Chemoradiation + - Upregulated Lost follow up 11
38 SIVAMMAL 45 F 60/14 IB2 WD Chemotherapy + surgery + - Downregulated Alive -Tumor free 11
39 SUMATHY 62 F 25/13 IB2 WD Chemotherapy + surgery - - Downregulated Alive -Tumor free 10
40 LALITHA 60 F 615/14 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 10
41 BANU 60 F 1068/13 IIIB MD Chemoradiation + - Upregulated Alive -Tumor free 17
42 MUNIAMMAL 56 F 378/14 IIB WD Chemotherapy + surgery + - Downregulated Lost follow up 11
43 PERIAMMAL 40 F 983/14 IB2 WD Chemotherapy + surgery + - Downregulated Alive -Tumor free 9
44 POONGAVANAM 45 F 1098/14 IIIB MD Chemoradiation + - Upregulated Lost follow up 3
45 SRIMATHY 35 F 1078/14 IB1 WD Surgery - - Downregulated Alive -Tumor free 8
46 KOTTI 38 F 739/14 IIB PD Chemotherapy + Surgery - + Upregulated Alive -Tumor free 10
47 ANJALAI 50 F 1211/14 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 8
48 SAROJA 65 F 1394/14 IIB MD Chemoradiation + - Downregulated Alive -Tumor free 7
49 RUKSHANA 72 F 780/14 IIA MD Chemoradiation + - Upregulated Alive -Tumor free 9
50 ROSE 60 F 1273/14 IIIB WD Chemoradiation - - Upregulated Alive-Recurrence 8
51 SAROJINI 45 F 1262/14 IB1 MD Surgery + - Upregulated Alive -Tumor free 8
52 POORANI 60 F 2117/14 IIIB MD Chemoradiation - - Downregulated Alive -Tumor free 4
53 RAJAKUMARI 50 F 603/14 IVB PD Chemotherapy - - Upregulated Alive-Recurrence 9
54 KAMATCHI 37 F 850/14 IIIB PD Chemoradiation + - Upregulated Alive -Tumor free 10
55 ARUNTHATHI 67 F 1649/14 IV B PD Chemotherapy - - Upregulated Dead-Tumor free 6
56 MALLIGA 50 F 1589/14 IIB WD Chemoradiation - - Upregulated Lost follow up 7
57 SARASWATHY 41 F 1393/14 IIA2 WD chemoradiation - - Downregulated Alive -Tumor free 8
58 VALLIAMMAL 60 F 1637/14 IIIB PD chemoradiation + - Upregulated Alive -Tumor free 6



